Aquestive Therapeutics: FDA approval decision outcome for Anaphylm sublingual epinephrine Jan 2026

The United States Food and Drug Administration issued a Complete Response Letter to Aquestive Therapeutics on January 30, 2026. The regulatory agency denied the New Drug Application for Anaphylm. Anaphylm is a sublingual film formulation of dibutepinephrine intended to treat severe Type I allergic reactions. The decision halted the anticipated January 31, 2026 approval target. The rejection triggered a massive selloff in the biotechnology sector. Investors wiped out millions in market capitalization within hours.

Anaphylm Regulatory Decision: 20 Essential Questions Answered

1. What is Anaphylm? Anaphylm is an orally administered epinephrine prodrug film.

2. Who manufactures Anaphylm? Aquestive Therapeutics developed the product.

3. What condition does the drug treat? The medication treats severe allergic reactions including anaphylaxis.

4. When did the FDA accept the New Drug Application? The agency accepted the submission in June 2025.

5. What was the original target action date? The scheduled decision date was January 31, 2026.

6. How does the medication enter the body? The film dissolves under the tongue for mucosal absorption.

7. What were the 2025 revenue figures for Aquestive? The company reported 44. 55 million dollars in revenue for 2025.

8. How much did the company lose in 2025? Net losses reached 83. 78 million dollars during the year.

9. What was the peak 52 week stock price before the decision? Shares reached 7. 55 dollars.

10. How patients participated in the pediatric trial? The pediatric study included 32 children.

11. What age group did the pediatric trial cover? The trial evaluated patients between 7 and 17 years old.

12. What was the mean epinephrine concentration in children? The concentration reached 280 picograms per milliliter at 10 minutes.

13. How fast did symptoms resolve in the adult trial? Median symptom resolution occurred in 12 minutes.

14. What is the active ingredient in the film? The active component is dibutepinephrine.

15. When did the company submit the application? Aquestive submitted the application in the quarter of 2025.

16. How long is the patent protection for the drug? The United States Patent and Trademark Office granted patents expiring in May 2037.

17. What alternative products currently exist? Patients currently rely on intramuscular autoinjectors.

18. How much cash did the company hold at the end of 2025? The firm held 121. 2 million dollars in cash and equivalents.

19. Did the FDA require an advisory committee meeting? The agency prepared for a possible meeting the exact date remains unspecified.

20. What was the market capitalization peak in 2025? The valuation reached approximately 730 million dollars.

Regulatory Timeline and Clinical Data

Aquestive Therapeutics submitted the New Drug Application in the quarter of 2025. The regulatory agency accepted the filing in June 2025. The scheduled Prescription Drug User Fee Act target action date was January 31, 2026. The Complete Response Letter detailed specific deficiencies in the application. The sudden rejection surprised investors. The company stock price plummeted immediately. The biotechnology sector experienced heavy trading volume following the announcement. Analysts downgraded the stock rating. The delay creates a major obstacle for the company. The firm previously expected to launch the product in early 2026.

Prior to the rejection, the company reported positive clinical trial results. The pediatric study concluded in April 2025. The trial included 32 children between 7 and 17 years old. The results showed a mean baseline adjusted epinephrine concentration of 280 picograms per milliliter at 10 minutes after administration. Adult trials demonstrated a median symptom resolution time of 12 minutes. The company presented these findings at medical conferences throughout 2025. The data showed consistent epinephrine absorption without impacting safety parameters. The formulation dissolves on contact without requiring water or swallowing. The packaging is thinner than a standard credit card.

Financial Position and Market Impact

The financial position of Aquestive Therapeutics weakened during 2025. The company reported 44. 55 million dollars in revenue for the year. This figure represented a 22. 6 percent decrease from the 57. 56 million dollars generated in 2024. Net losses expanded to 83. 78 million dollars. The company held 121. 2 million dollars in cash and equivalents at the end of 2025. The market capitalization peaked at approximately 730 million dollars in 2025 before the regulatory setback. The firm relies heavily on partnerships for revenue generation. The rejection forces the company to burn through cash reserves while resolving the regulatory demands.

Intellectual Property and Steps

The United States Patent and Trademark Office issued two new patents for the product in October 2025. These patents extended intellectual property protection until May 2037. The composition of matter patents cover formulations designed to enable oral mucosal absorption. The company must resolve the deficiencies outlined in the Complete Response Letter. Executives plan to request a Type A meeting with the regulatory agency. The delay pushes any future commercial launch far beyond the original early 2026 target. The firm needs to allocate additional capital to resolve the regulatory matters. The competitive market for severe allergy treatments remains dominated by autoinjector devices.

Our data science and investigative desks demand clarity. We present the core questions driving this inquiry.

1. What is Anaphylm? It is an orally delivered epinephrine film.
2. When was the PDUFA date? The target was January 31, 2026.
3. What did the FDA problem? A Complete Response Letter.
4. Did the drug fail safety tests? No.
5. Did the drug fail efficacy tests? No.
6. What caused the rejection? Human factors validation deficiencies.
7. What specific packaging problem was? Difficulty opening the primary pouch.
8. What administration problem was? Incorrect film placement on the tongue.
9. What new study is required? A supportive pharmacokinetics study.
10. When Aquestive resubmit? The company the third quarter of 2026.
11. How did the stock react? Shares plummeted from $6. 21 to $3. 91.
12. Is there legal? Yes. A securities fraud class action is underway.
13. How much cash does Aquestive hold? The company reported $120 million at the end of 2025.
14. Who is the CEO? Daniel Barber leads the company.
15. Are European regulators demanding new trials? No.
16. When is the Canadian submission expected? The half of 2026.
17. What is the pediatric dose? Children weighing over 66 pounds receive a 12 milligram dose.
18. Who is the main competitor? ARS Pharmaceuticals with its neffy nasal spray.
19. When do the patents expire? The core patents expire in May 2037.
20. the FDA require an Advisory Committee? The agency previously stated it would not require one.

The United States Food and Drug Administration established a Prescription Drug User Fee Act target action date of January 31, 2026, for the Anaphylm New Drug Application. Aquestive Therapeutics submitted the application in early 2025 after completing adult and pediatric clinical trials. The regulatory agency issued a Complete Response Letter just before the deadline. The rejection centered on human factors validation rather than the chemical efficacy or safety profile of the dibutepinephrine film. Test subjects demonstrated difficulty opening the primary packaging pouch. subjects placed the film incorrectly on their tongues. The agency requires a supportive pharmacokinetics study to evaluate these administration procedures.

Aquestive Therapeutics ended 2025 with $121. 2 million in cash and cash equivalents. The company generated $13. 0 million in revenue during the fourth quarter of 2025, primarily from manufacturing agreements for products like Suboxone. The FDA rejection triggered an immediate market selloff. Shares fell from $6. 21 to $3. 91. The sudden drop erased millions in market capitalization and prompted a securities fraud class action lawsuit. Chief Executive Officer Daniel Barber stated the company plans to resubmit the New Drug Application in the third quarter of 2026. The company expects to end 2026 with $70 million in cash.

The competitive environment for needle free epinephrine is expanding. ARS Pharmaceuticals received FDA approval for its neffy nasal spray in August 2024 for adults and children weighing at least 66 pounds. The agency approved a lower dose neffy spray for children weighing between 30 and 66 pounds in March 2025. Aquestive designed Anaphylm to compete directly in this sector. The sublingual film weighs less than one ounce and is smaller than a standard credit card. The product dissolves on contact without requiring water.

Aquestive Therapeutics secured long term intellectual property protection for Anaphylm before the regulatory setback. The United States Patent and Trademark Office issued U. S. patent numbers 12, 427, 121 and 12, 443, 850 in October 2025. These patents cover the proprietary composition of the epinephrine prodrug and the sublingual film delivery method. Both patents expire on May 4, 2037. This exclusivity period gives the company a financial incentive to resolve the human factors validation problems and secure market entry.

Clinical data from 2025 demonstrated the film’s viability in younger populations. A Phase 1 pediatric trial enrolled 32 children ages 7 to 17 who weighed at least 66 pounds. Each participant received a single 12 milligram dose of Anaphylm placed under the tongue. Researchers measured epinephrine levels in the blood and tracked changes in heart rate and blood pressure. The pediatric responses matched the absorption rates and safety profiles observed in adult trials. The company plans to develop a lower dose formulation for children weighing between 30 and 66 pounds once the primary 12 milligram dose receives approval.

The company continues its international expansion strategy even with the United States regulatory delay. Aquestive Therapeutics remains on schedule to submit regulatory applications for Anaphylm in Canada and the European Union during 2026. European regulators do not require new clinical trials for the submission. The company extended a revenue sharing agreement with RTW Investments through June 30, 2027. This agreement provides financial stability while the company conducts the required supportive pharmacokinetics study and prepares for the third quarter 2026 resubmission.

The FDA delivered the Complete Response Letter just one day before the Prescription Drug User Fee Act target action date. The agency identified serious flaws in the human factors validation study. Regulators noted that patients experienced difficulty opening the primary packaging pouch. The FDA also observed instances of incorrect film placement and premature removal of the film from the tongue. The agency concluded these usability errors could cause significant safety risks during a life threatening anaphylactic event.

Anaphylm Regulatory Decision: Questions 4 Through 20 Answered

4. When did Aquestive submit the New Drug Application? Aquestive submitted the application on April 1, 2025.

5. When did the FDA accept the application? The agency accepted the submission on June 16, 2025.

6. What was the original Prescription Drug User Fee Act target date? The agency assigned a target date of January 31, 2026.

7. What is a Complete Response Letter? A formal communication indicating an application cannot receive approval in its present form.

8. Did the FDA question the drug efficacy? No, the agency did not question the efficacy.

9. Were there chemistry and manufacturing deficiencies? The FDA noted no chemistry, manufacturing, or controls deficiencies.

10. What was the primary reason for rejection? Flaws in the human factors validation study.

11. How total administrations occurred in the clinical program? The program included 967 total administrations.

12. How subjects participated in the clinical trials? The trials included 411 subjects.

13. How individuals failed to open the pouch in the human factors study? Only one individual, a child, failed to open the child resistant pouch.

14. How users tore the film during opening? Six people tore the film while opening the pouch.

15. Did users who tore the film receive a full dose? Yes, all six individuals received a full dose.

16. How participants removed the film prematurely? Four participants removed the film early.

17. Why did participants remove the film? Two reported a bad taste, and two reported a burning sensation.

18. Does Aquestive plan to conduct a new human factors study? Yes, the company plans to conduct a new validation study.

19. Did the FDA require new adult clinical efficacy trials? No additional adult clinical efficacy trials are required.

20. When does Aquestive plan to resubmit the application? The company a resubmission in the third quarter of 2026.

The regulatory feedback centers entirely on the human factors validation study. Aquestive Therapeutics designed this study to evaluate how real patients interact with the Anaphylm packaging and administration process. The clinical development program for Anaphylm involved 11 independent clinical studies. These trials included 967 total administrations across 411 subjects. The FDA scrutinized the specific physical interactions between the patients and the product packaging.

During the human factors validation study, regulators zeroed in on three specific user errors. The agency highlighted pouch opening difficulties. Data from the study indicates that only one individual failed to open the child resistant pouch. This single failure involved a pediatric patient. Regulators then noted film tearing. Six individuals tore the sublingual film while attempting to open the primary packaging. Aquestive reported that all six of these individuals still received a full dose of dibutepinephrine. The agency also documented premature film removal. Four participants removed the film from their tongue before it fully dissolved. Two of these participants reported an unpleasant taste, and two reported a burning sensation.

The FDA requires a flawless user experience for emergency anaphylaxis treatments. Patients must administer the drug under extreme physical and emotional distress. Regulators concluded that the documented usability errors introduce unacceptable risks. A patient experiencing a severe Type I allergic reaction cannot afford delays caused by torn packaging or premature removal due to sensory discomfort.

Human Factors Validation Study Error Frequencies

The agency did not question the underlying science of the dibutepinephrine formulation. The Complete Response Letter contained no chemistry, manufacturing, or controls deficiencies. Regulators did not request additional adult clinical efficacy trials. The pharmacokinetic data, bracketing data, and repeat dose safety metrics met regulatory standards. The rejection rests entirely on the physical delivery mechanics and the patient experience.

Aquestive must execute a specific remediation plan. The company plans to modify the pouch opening design to reduce friction and tearing. Engineers are updating the administration instructions to provide clearer guidance on film placement. The company is revising both the pouch and carton labeling to address the FDA feedback. Once these modifications are complete, Aquestive must conduct a new human factors validation study. The FDA also requires a new single dose pharmacokinetic study to verify that the packaging changes do not alter the drug delivery profile.

1. What is Anaphylm? Anaphylm is a sublingual film formulation of epinephrine.

2. Who manufactures Anaphylm? Aquestive Therapeutics manufactures the product.

3. What is the stock ticker for Aquestive Therapeutics? The company trades under the ticker AQST.

4. What condition does Anaphylm treat? The film treats severe allergic reactions including anaphylaxis.

5. When did the FDA accept the new drug application? The FDA accepted the application in June 2025.

6. What was the original target action date? The target action date was January 31, 2026.

7. What happened on January 9, 2026? Aquestive disclosed an FDA letter identifying application deficiencies.

8. How did the stock market react on January 9? The stock price fell 37 percent in one day.

9. What was the closing price on January 8, 2026? The stock closed at $6. 21 per share.

10. What was the closing price on January 9, 2026? The stock closed at $3. 91 per share.

11. How much value did the stock lose per share? The stock lost $2. 30 per share.

12. Did the FDA specify the deficiencies in the initial letter? The FDA did not specify the exact nature of the deficiencies in the January 9 letter.

13. What did Cantor analysts do following the announcement? Cantor lowered their price target from $15 to $8.

14. What did Oppenheimer analysts state? Oppenheimer described the communication as a meaningful setback.

15. When did the FDA problem a Complete Response Letter? The FDA issued the letter on January 30, 2026.

16. What did the Complete Response Letter state? The letter detailed human factors validation matters.

17. What specific packaging matters were mentioned? The FDA noted observed difficulties with pouch opening and film placement.

18. Did the FDA question the efficacy of the drug? The FDA did not raise efficacy or safety questions.

19. How did the stock react after the Complete Response Letter details emerged? The share price increased by 35 percent.

20. When does Aquestive plan to resubmit the application? The company plans to resubmit in the third quarter of 2026.

Market Devastation and Equity Collapse

Financial markets reacted with immediate selling pressure on January 9, 2026. Aquestive Therapeutics traded at $6. 21 per share on January 8, 2026. The company then disclosed a communication from the Food and Drug Administration regarding unresolved application deficiencies. The stock price fell to $3. 91 per share by the close of trading on January 9. This represents a loss of $2. 30 per share. The 37 percent equity contraction erased shareholder value. Wall Street analysts responded immediately. Cantor reduced its price target for the company from $15 to $8. Oppenheimer analysts published a report stating the stock was pricing in a Complete Response Letter.

Aquestive must conduct a new pharmacokinetics study. The FDA requires this trial to evaluate how the newly modified packaging and updated instructions affect drug absorption. The company redesigned the pouch opening method to resolve the usability complaints. The agency explicitly stated that the human factors study and the pharmacokinetics study can proceed concurrently. No additional large clinical efficacy trials were requested.

The regulatory decision centers entirely on administration mechanics rather than the chemical composition of the drug. The United States Food and Drug Administration identified specific deficiencies in the human factors validation study. Trial participants experienced difficulty opening the foil pouch. Subjects also placed the sublingual film incorrectly inside their mouths. The agency determined these usability problems could cause serious safety risks during an emergency anaphylactic event. Aquestive Therapeutics responded by modifying the pouch opening design. The company also updated the printed instructions for use and revised the carton labeling.

Because the company altered the physical packaging and the instructions, the regulatory agency mandated a single supportive pharmacokinetics study. This trial measure the absorption rate of dibutepinephrine into the bloodstream using the new packaging format. The clinical pharmacology division requested this specific trial to guarantee that the new pouch design does not degrade the fast absorption rate of the drug. The original data proved that the sublingual film delivers epinephrine concentrations comparable to manual injections. The median time to maximum concentration reached 15 minutes for the sublingual film. The manual injection required 50 minutes to reach maximum concentration. The agency needs absolute certainty that the new foil packaging does not alter these metrics. The company must prove that patients can open the new pouch and apply the film just as quickly as they did in the previous trials. The trial measure the maximum amount of epinephrine measured in blood plasma. Researchers also measure the total exposure over time. These metrics form the foundation of the resubmission package. Aquestive Chief Executive Officer Daniel Barber confirmed the company has already designed the trial structure for the new validation study.

Anaphylm Regulatory Decision: Questions 4 Through 20 Answered

4. Why did the regulatory agency deny immediate approval? The agency identified human factors validation problems.

5. What specific problems did the agency identify? Trial participants experienced difficulty opening the pouch and placed the film incorrectly.

6. Did the agency question the drug efficacy? No. The agency raised no efficacy concerns.

7. Were there manufacturing defects? The agency noted no chemistry or manufacturing defects.

8. What is a pharmacokinetics study? It measures how the body absorbs and processes a drug.

9. Why is a new pharmacokinetics study required? The agency wants to verify that packaging changes do not alter drug absorption.

10. Can the company run the required studies? Yes. The agency permits concurrent human factors and pharmacokinetics trials.

11. When does Aquestive plan to resubmit the application? The company the third quarter of 2026.

12. How much cash does Aquestive hold? The company reported 120 million dollars at the end of 2025.

13. the agency require more large clinical trials? No. The agency requested only a single supportive pharmacokinetics study.

14. What is a Type A meeting? It is a formal discussion requested by a company to resolve regulatory disputes or clarify a Complete Response Letter.

15. Has Aquestive changed the packaging? The company redesigned the pouch opening design.

16. Did the agency require an advisory committee meeting? The agency previously determined an advisory committee was unnecessary.

17. How clinical studies supported the original application? The original submission included 11 clinical studies.

18. How total administrations occurred in prior trials? Researchers recorded 967 total administrations.

19. How participants tested Anaphylm previously? The clinical program included 411 participants.

20. the company update the instructions? Yes. Aquestive revised the instructions for use alongside the packaging changes.

Clinical Trial History and Future Milestones

The original New Drug Application relied on an extensive clinical history. Aquestive conducted 11 clinical studies before submitting the application. These trials involved 411 participants and included 967 total administrations of the sublingual film. The agency reviewed this data and found no chemistry, manufacturing, or controls defects. The agency also accepted the comparability data comparing Anaphylm to existing intramuscular epinephrine injections. The absence of efficacy complaints provides a clear regulatory route forward. The company request a Type A meeting with the agency to finalize the resubmission strategy. Aquestive expects to resubmit the application in the third quarter of 2026.

Financial stability remains a core component of the resubmission strategy. Aquestive ended 2025 with 120 million dollars in cash and cash equivalents. The company stated this capital is sufficient to fund the required human factors validation study and the supportive pharmacokinetics trial. The company also continues to pursue international approvals. Aquestive plans to submit a New Drug Submission to Health Canada in the half of 2026. The European Medicines Agency confirmed that no further clinical trials are needed for European submission. The company file its European marketing authorization application in the second half of 2026.

Pharmacokinetics Data Comparison

The new pharmacokinetics trial measure specific absorption metrics against the established baseline. The table details the primary metrics recorded during the original clinical program.

The following chart illustrates the timeline for the upcoming regulatory milestones.

The regulatory setback did not invalidate the underlying science. The original New Drug Application included 11 independent clinical studies. These trials encompassed 967 total administrations across 411 subjects. The data proved that the sublingual film delivers a pharmacokinetics profile comparable to leading epinephrine auto injectors. The FDA raised no concerns regarding comparability data or chemistry and manufacturing controls.

The Phase 3 pivotal trial operated as a two part single center open label randomized study. Researchers recruited 64 adult subjects to evaluate the pharmacokinetic profile of the epinephrine prodrug candidate. The trial measured the time to maximum concentration for the sublingual film against established injectable treatments. The median time to maximum concentration for Anaphylm registered at 12 minutes. This metric beat EpiPen at 20 minutes and Auvi Q at 30 minutes. Manual intramuscular injection recorded a median time of 50 minutes. The sublingual film achieved rapid widespread exposure while maintaining comparable exposure levels for 30 minutes post dosing.

Aquestive Therapeutics executed a separate self administration study to verify usability under stress. The data proved that pharmacokinetics remain comparable whether patients administer the film themselves or receive it from healthcare providers. The median time to maximum concentration hit 15 minutes across both the self administered and provider administered cohorts in this specific trial. The corresponding manual injection arm administered by professionals took 50 minutes to reach maximum concentration.

The physical characteristics of the drug delivery system remain unchanged. The polymer matrix based film matches the size of a standard postage stamp and weighs less than one ounce. The prodrug dissolves on contact with the oral mucosa. Patients do not need water or swallowing action to absorb the medication. The primary packaging is thinner than a standard credit card and withstands extreme weather conditions including direct sunlight and freezing temperatures. The FDA raised no objections to these physical specifications.

Aquestive Therapeutics also completed a pediatric study involving 32 patients aged 7 to 17 years weighing more than 30 kilograms. The results aligned with adult data. Pediatric subjects showed a mean baseline adjusted epinephrine concentration of 280 picograms per milliliter at 10 minutes after receiving a 12 milligram dose. Adult subjects in previous trials recorded 330 picograms per milliliter at the same interval. The FDA review process incorporates these pediatric findings to evaluate labeling for younger demographics.

The clinical program tested the drug under real world conditions through the Oral Anaphylm Symptom Intervention Study. Researchers administered the film to 36 adults with Oral Allergy Syndrome. The trial included single and repeat dosing with and without oral allergen challenges. The sublingual film matched or exceeded intramuscular epinephrine across all key pharmacokinetic parameters. Oral swelling did not alter drug absorption. The median symptom resolution time clocked in at 12 minutes. Mean angioedema symptom resolution occurred within 5 minutes.

The regulatory denial centered entirely on human factors validation. The agency documented instances where users struggled to open the packaging pouch or placed the film incorrectly under the tongue. The FDA requested a new human factors validation study and a single pharmacokinetics trial to verify that packaging modifications do not alter drug delivery. The agency explicitly stated that no additional efficacy trials are required.

Anaphylm Regulatory Decision: Questions 4 through 8

4. Did the FDA reject the drug because it does not work?
No. The FDA confirmed the efficacy data and requested no new efficacy trials.

5. What specific problems did the FDA identify?
The agency documented difficulties with opening the packaging pouch and incorrect placement of the film by users.

6. How fast does Anaphylm work compared to an EpiPen?
Anaphylm reaches maximum concentration in 12 minutes. EpiPen takes 20 minutes.

7. Is the drug safe for children?
Clinical trial data verified consistent safety and absorption in children aged 7 to 17 weighing over 30 kilograms.

8. Does mouth swelling prevent the film from working?
Clinical data proved that oral swelling from allergic reactions does not block epinephrine absorption from the film.

Corporate survival depends on liquidity. Aquestive ended the 2025 fiscal year with approximately $120 million in cash and cash equivalents. The company secured a $75 million strategic funding agreement with RTW Investments in August 2025. This capital reserve provides the necessary runway to fund the mandated human factors studies and sustain operations through the projected 2026 resubmission timeline.

20 Questions Answered: Aquestive Therapeutics Financial Reserves

1. What was the total cash balance for Aquestive Therapeutics at the end of 2025?
Aquestive Therapeutics reported $121. 2 million in cash and cash equivalents on December 31, 2025.

2. How much revenue did the company generate in the fourth quarter of 2025?
The company generated $13. 0 million in total revenue during the fourth quarter of 2025.

3. What was the total revenue for the full year 2025?
Aquestive recorded $44. 5 million in total revenue for the entire 2025 fiscal year.

4. Did Aquestive secure new funding in 2025?
Yes. The company secured an $85 million equity offering and a $75 million strategic funding agreement in August 2025.

5. Who provided the $75 million strategic funding?
RTW Investments provided the $75 million strategic funding agreement.

6. What condition applies to the RTW Investments funding?
The capital becomes available subject to the United States Food and Drug Administration approving Anaphylm.

7. How shares did Aquestive sell in the August 2025 equity offering?
The company sold 21, 250, 000 shares of common stock.

8. What was the price per share in the August 2025 offering?
The shares were priced at $4. 00 each.

9. What was the net loss for the fourth quarter of 2025?
The company reported a net loss of $31. 9 million for the fourth quarter of 2025.

10. What drove the high net loss in the fourth quarter?
Elevated legal expenses and pre commercial spending drove the net loss higher.

11. What was the non GAAP adjusted EBITDA loss for 2025?
The non GAAP adjusted EBITDA loss was $49. 7 million for the full year 2025.

12. How long the current cash reserves last?
Management projects the current cash balance fund operations into 2027.

13. What is the projected cash balance for the end of 2026?
The company guides to end the 2026 fiscal year with $70 million in cash and cash equivalents.

14. How much did research and development cost in the fourth quarter of 2025?
Research and development expenses totaled $3. 2 million in the fourth quarter of 2025.

15. Did manufacturing revenue increase in 2025?
Yes. Manufacture and supply revenue increased to $12. 0 million in the fourth quarter of 2025.

16. How doses did the company manufacture in the fourth quarter of 2025?
Aquestive manufactured 47. 25 million doses in the fourth quarter of 2025.

17. What legal settlement impacted the 2025 financials?
Aquestive entered into a confidential legal settlement with Neurelis in December 2025.

18. Who led the August 2025 equity offering?
RTW Investments led the equity offering with participation from Samsara BioCapital and others.

19. What is the primary use for the raised capital?
The company intends to use the funds to advance the launch and commercialization of Anaphylm.

20. Does the company have long term debt?
Aquestive held $45. 0 million in long term debt at the end of 2025.

Capital Injections and Equity Offerings

Aquestive Therapeutics fortified its balance sheet during the third quarter of 2025. The company executed an $85 million underwritten registered direct offering in August 2025. Aquestive sold 21, 250, 000 shares of common stock at a price of $4. 00 per share. RTW Investments led the offering. Samsara BioCapital, EcoR1 Capital, and Perceptive Advisors also participated in the equity purchase. The gross proceeds provided immediate liquidity to fund ongoing operations and pre commercialization activities.

The company secured a parallel $75 million strategic funding agreement with RTW Investments. This capital remains contingent upon the United States Food and Drug Administration granting regulatory approval for Anaphylm. The combined financing structure ensures Aquestive possesses the capital required to execute a commercial launch while mitigating immediate dilution risks. The cash balance peaked at $129. 1 million at the end of the third quarter of 2025 before settling at $121. 2 million by December 31, 2025.

Operating Expenses and Cash Burn

Aquestive operates with a high cash burn rate. The company reported a net loss of $31. 9 million in the fourth quarter of 2025. The full year non GAAP adjusted EBITDA loss reached $49. 7 million. Selling, general, and administrative expenses surged to $32. 8 million in the fourth quarter. This increase resulted from elevated legal expenses tied to a confidential settlement with Neurelis in December 2025.

Research and development expenses decreased to $3. 2 million in the fourth quarter of 2025. The reduction reflects the completion of major clinical trials for the Anaphylm development program. The company maintains $45. 0 million in long term debt. The debt obligations require consistent cash flow management.

Manufacturing Revenue Base

The manufacturing and supply segment provides the primary revenue stream for Aquestive. Total revenues reached $44. 5 million for the full year 2025. The company generated $13. 0 million in the fourth quarter. Manufacture and supply revenue accounted for $12. 0 million of the fourth quarter total.

Aquestive manufactured 47. 25 million doses in the fourth quarter of 2025. The volume represents the highest quarterly production in recent periods. The company produces Suboxone sublingual film for Indivior and Sympazan oral film for Assertio Holdings. This baseline revenue partially offsets the high operating costs associated with the Anaphylm regulatory process.

Legal consequences followed the stock collapse. Law firms initiated a securities fraud class action lawsuit against Aquestive Therapeutics. The complaint alleges that management misled investors by characterizing FDA interactions as routine during the November 2025 earnings call. The lawsuit claims executives failed to disclose the severity of the packaging deficiencies. The court established a lead plaintiff deadline of May 4, 2026.

Litigation and Financial Data: 20 Questions Answered

1. Who is the lead defendant in the class action lawsuit? Aquestive Therapeutics is the primary corporate defendant.

2. What is the ticker symbol for Aquestive Therapeutics? The company trades under the symbol NASDAQ: AQST.

3. When did the company hold its third quarter 2025 earnings call? Management hosted the call on November 6, 2025.

4. Who was the Chief Executive Officer during this period? Daniel Barber held the position of Chief Executive Officer.

5. Who served as the Chief Financial Officer? Ernie Toth operated as the Chief Financial Officer.

6. What was the target Prescription Drug User Fee Act date for Anaphylm? The regulatory agency set the date for January 31, 2026.

7. What did management claim about the regulatory Advisory Committee? Executives stated the regulatory agency decided not to convene a committee.

8. How much capital did Aquestive raise in August 2025? The company secured $85 million in gross proceeds.

9. What was the share price during the August 2025 offering? The underwriters priced the shares at $4. 00 each.

10. How shares did the company sell in the August 2025 offering? The offering included 21. 25 million shares of common stock.

11. What was the closing stock price on November 17, 2025? The stock reached a closing price of $5. 39 per share.

12. What was the average analyst price target in November 2025? Financial analysts published an average target of $10. 51 per share.

13. How institutional shares were held in late 2025? Institutional investors controlled 70. 7 million shares.

14. Which firm held the largest institutional stake? Bratton Capital Management maintained the largest single position.

15. How shares did Bratton Capital Management own? The firm held exactly 9. 81 million shares.

16. What percentage of the company did RTW Investments own? RTW Investments controlled 5. 12 percent of outstanding shares.

17. How shares did Perceptive Advisors hold? The investment firm owned 3. 76 million shares.

18. What is the lead plaintiff deadline for the lawsuit? The federal court established a deadline of May 4, 2026.

19. What specific product is at the center of the litigation? The lawsuit focuses entirely on the Anaphylm sublingual film.

20. What regulatory submission is under scrutiny? The New Drug Application for Anaphylm forms the basis of the complaint.

Aquestive Therapeutics hosted its third quarter earnings call on November 6, 2025. Chief Executive Officer Daniel Barber and Chief Financial Officer Ernie Toth addressed investors. Barber stated the New Drug Application remained on track for the January 31, 2026 target date. He told attendees the regulatory agency decided not to convene an Advisory Committee. Management reported active communication with regulators and confirmed the company responded to all information requests. The lawsuit alleges these statements created a false impression of regulatory progress.

The litigation encompasses investors who purchased shares during the August 2025 public offering. Aquestive Therapeutics raised $85 million by selling 21. 25 million shares of common stock. The company priced the shares at $4. 00 each. RTW Investments led the offering. Samsara BioCapital and EcoR1 Capital participated in the funding round. Management allocated the proceeds to fund the commercial launch of Anaphylm. Plaintiffs claim the company secured this capital while withholding material facts about the packaging defects.

Institutional investors held massive positions before the regulatory rejection. Financial filings from late 2025 show institutions owned 70. 7 million shares. This represented 56. 4 percent of outstanding shares. Bratton Capital Management controlled 9. 81 million shares. RTW Investments retained 6. 25 million shares. Perceptive Advisors increased its position to 3. 76 million shares. The stock price closed at $5. 39 on November 17, 2025. Analysts published an average price target of $10. 51 per share during the same week. The subsequent stock collapse erased millions in value for these institutional holders.

The legal filings detail the timeline of the packaging defects. Anaphylm relies on a polymer matrix film design. The primary packaging is smaller than a standard credit card. The company designed the wrapper to withstand rain and sunlight exposure. Plaintiffs state the regulatory agency identified flaws in this specific packaging material long before the January 2026 rejection. The complaint alleges Aquestive executives knew the packaging failed to meet regulatory standards during the third quarter of 2025. The lawsuit seeks compensatory damages for all shareholders who purchased stock between August 15, 2025, and January 30, 2026.

Sell side analysts rapidly adjusted their financial models. Oppenheimer published a report calling the FDA communication a meaningful setback. Analysts noted that the market heavily relied on management assurances regarding the January 2026 approval. The sudden regulatory halt forced analysts to slash price. Market sentiment shifted from extreme optimism to cautious skepticism.

Anaphylm Regulatory Decision: 20 Essential Questions Answered

9. Which firm called the FDA communication a meaningful setback? Oppenheimer published a report detailing the regulatory delay.

10. What was the peak consensus price target in late 2025? The average target reached $10. 51 in November 2025.

11. How shares did EcoR1 Capital purchase in the third quarter of 2025? The firm acquired 2. 62 million shares.

12. What rating did JMP Securities problem in October 2025? The firm issued a Market Outperform rating.

Investment banks built aggressive revenue models based on the anticipated approval timeline. Cantor Fitzgerald issued an Overweight rating with a $15. 00 price target on August 19, 2025. JMP Securities maintained a Market Outperform rating and raised its target to $12. 00 on October 9, 2025. Piper Sandler set an $8. 00 target on November 7, 2025. The consensus price target among ten analysts climbed to $10. 51 by November 17, 2025. Financial models projected probability adjusted peak sales of $700 million for the sublingual epinephrine film.

Institutional investors accumulated substantial positions during the third quarter of 2025. EcoR1 Capital added 2. 62 million shares to its portfolio. Samsara BioCapital purchased 2. 50 million shares. Perceptive Advisors increased its holdings by 1. 56 million shares. Vanguard Group acquired 1. 33 million shares. Bratton Capital Management held 9. 81 million shares. This position represented 8. 04 percent ownership of the company. RTW Investments held 6. 25 million shares. The total number of shares owned by institutions increased by 33. 78 percent to 70. 71 million shares by mid November 2025. The put to call ratio dropped to 0. 26. This metric indicated heavy speculative buying in the options market. The concentrated ownership structure amplified the selling pressure when the regulatory decision became public.

Aquestive Therapeutics reported $12. 8 million in revenue for the third quarter of 2025. This figure represented a 5. 43 percent decrease from the same period in the prior year. The market ignored the revenue contraction. Investors focused entirely on the Anaphylm approval prospects. The company later reported $13. 0 million in revenue for the fourth quarter of 2025. The fourth quarter net loss reached $31. 9 million. Selling, general, and administrative expenses surged to $32. 8 million. The cash burn rate accelerated as the company hired 75 sales representatives to prepare for the anticipated launch. The management team increased the sales force size by 50 percent from previous guidance.

Aquestive Therapeutics closed at $6. 50 per share on December 29, 2025. The valuation reflected absolute confidence in a favorable regulatory outcome. The FDA communication shattered this confidence. Cantor Fitzgerald immediately lowered its price target. Oppenheimer warned clients that the identified deficiencies put the drug at serious risk of a Complete Response Letter. The sudden downgrade wave triggered a large liquidation event.

The regulatory failure exposed the fragility of the biotechnology sector. Retail traders and institutional funds suffered identical losses. The company held $121. 2 million in cash reserves at the end of December 2025. Management claimed this capital would support operations through the remediation process. Analysts remained unconvinced. The required human factors validation study and the additional pharmacokinetic trial demand significant capital expenditures. The revised timeline pushes chance commercialization into 2027.

Market participants completely repriced the asset. The stock price collapsed as funds exited their positions. The trading volume surged as panic selling overwhelmed the bid orders. The absence of a clear route forward left investors stranded. The regulatory delay destroyed the mover advantage. Competing pharmaceutical companies gained valuable time to advance their own needle free epinephrine candidates. The financial damage extended beyond the immediate market capitalization loss. The company must rebuild credibility with a highly skeptical investment community.

The United States rejection does not halt international ambitions. Aquestive continues its global regulatory strategy. The European Medicines Agency confirmed that no further clinical trials are required prior to submission. The company plans to submit a marketing authorization application in Europe in the second half of 2026. Aquestive also expects to file a New Drug Submission with Health Canada in the half of 2026.

Anaphylm International Strategy: 20 Questions Answered

The international strategy for the sublingual epinephrine film gained momentum throughout 2025. Aquestive Therapeutics submitted an initial briefing book to the European Medicines Agency in July 2025. The submission marked the formal step toward securing approval outside the United States. The European regulatory body reviewed the adult clinical trial data. The agency concluded that the existing studies provide sufficient evidence for a marketing authorization application. The company does not need to conduct new efficacy trials for the European market.

Health Canada also engaged with the pharmaceutical manufacturer in 2025. The Canadian health authority granted a formal meeting in the third quarter of 2025. The discussions centered on the requirements for a New Drug Submission. Aquestive executives confirmed the meeting provided clear guidance for the 2026 filing. The company operates pediatric trials at multiple sites across Canada and the United States. The pediatric data support the global applications.

Financial resources remain available for these international filings. Aquestive reported approximately 93 million dollars in proforma cash and cash equivalents at the end of December 2024. The company generated revenue by manufacturing millions of doses for existing licensing agreements. The manufacturing volume reached 43 million doses in the fourth quarter of 2024. The steady revenue from legacy products funds the regulatory expansion for the epinephrine film.

The United Kingdom represents another primary market for the sublingual film. Aquestive initiated formal communications with the Medicines and Healthcare Products Regulatory Agency in 2025. The company expects direct feedback from the British agency in the quarter of 2026. The manufacturer relies on its history of international commercialization to navigate these distinct regulatory bodies. The company currently produces six approved medications distributed across six continents. This established manufacturing network provides the infrastructure needed to supply the European and Canadian markets upon approval.

Target Market by Region

Children represent a serious demographic for allergy medications. Aquestive successfully completed a pediatric study in November 2025. The Phase 1 trial enrolled 32 children ages 7 to 17 weighing at least 66 pounds. Each child received a single 12 milligram dose of Anaphylm. The study confirmed that pediatric absorption rates and safety profiles matched adult data. The vast majority of adverse events were mild and transient.

Anaphylm Pediatric Trial: Essential Questions Answered

11. What was the median age of the pediatric participants? The median age of the children in the trial was 13 years.

12. What was the median weight of the enrolled children? The median weight of the participants was 47. 15 kilograms.

13. How fast did the medication reach maximum concentration in children? The median time to maximum concentration was 10 minutes.

14. Did the pediatric trial report any serious adverse events? The researchers reported zero serious adverse events during the study.

15. What was the maximum epinephrine concentration recorded in the pediatric group? The geometric mean maximum concentration reached 568. 6 picograms per milliliter.

The open label trial took place across multiple sites in the United States and Canada. Researchers evaluated 32 pediatric patients with a documented history of severe allergic reactions. The demographic breakdown showed that boys made up 62. 5 percent of the study population. The participants had a median body mass index of 18. 7 kilograms per square meter. Each patient received the medication sublingually while in an upright position. The clinical team prohibited food consumption for two hours prior to dosing. Water consumption remained permitted until the study procedures began. The primary objective centered on measuring the pharmacokinetic and pharmacodynamic responses to the 12 milligram dose.

The pharmacokinetic data confirmed rapid absorption in the pediatric group. The median time to maximum concentration was 10 minutes for children. Adult patients in previous trials recorded a median time of 12 minutes. The geometric mean maximum concentration reached 568. 6 picograms per milliliter in the pediatric cohort. Adult trials previously recorded a maximum concentration of 470. 2 picograms per milliliter. The baseline adjusted epinephrine concentration at the 10 minute mark measured approximately 280 picograms per milliliter for children. Adult patients showed a concentration of 330 picograms per milliliter interval. The clinical investigators noted that the pediatric maximum concentration slightly exceeded the adult measurements. The statistical analysis showed no meaningful difference between the two populations.

The pharmacodynamic results aligned with the expected physiological responses to epinephrine. The researchers recorded transient rises in systolic blood pressure. The patients also experienced temporary increases in diastolic blood pressure and heart rate. These physiological changes confirm that the medication actively enters the bloodstream and triggers the necessary cardiovascular responses to reverse anaphylaxis. The clinical team observed that these effects coincided with the early reaction period. The rapid onset of physiological changes provides a strong indicator of clinical dependability.

The safety profile of the sublingual film remained consistent throughout the testing phase. The medical staff monitored all participants closely after the administration of the dose. The trial recorded zero serious adverse events. The reported side effects matched the known safety profile of epinephrine. The transient nature of the blood pressure and heart rate changes required no additional medical intervention. The study participants tolerated the sublingual administration well. The film dissolves upon contact with the mucosal tissue. The patients do not need to swallow the medication or consume water. The packaging protects the film from environmental factors like rain and sunlight. The compact size allows patients to carry the medication easily.

Aquestive Therapeutics plans to use these pediatric results to support broader labeling. The company submitted the New Drug Application to the United States Food and Drug Administration. The regulatory agency accepted the submission in June 2025. The current application seeks approval for adults and children weighing 30 kilograms or more. The company executives stated that they plan to seek approval for a lower dose version in the future. The proposed lower dose would target smaller children weighing between 15 and 30 kilograms. The successful completion of the pediatric trial satisfies the regulatory requirement for testing the 12 milligram dose in the 30 kilogram and above weight class. The data from this trial forms a central component of the final regulatory review.

The clinical program included a of its kind Oral Allergy Syndrome challenge study. The trial tested the film in patients experiencing active mouth swelling and itching. Results demonstrated rapid resolution of allergen related symptoms beginning just two minutes after administration. The average time to complete symptom resolution was 12 minutes. The pharmacokinetics profile remained consistent even during active oral allergic reactions.

The United States Food and Drug Administration requested this specific trial to determine if localized mouth swelling impacts the absorption of the dibutepinephrine film. Anaphylaxis causes severe swelling of the lips, tongue, and airways. Regulators needed proof that the sublingual delivery method works during an active allergic event. Aquestive Therapeutics designed a two part investigation to evaluate the pharmacokinetics and pharmacodynamics of Anaphylm in adults with allergen induced oral physiological changes. The study enrolled 36 adults with confirmed allergies to raw fruits such as apples, kiwis, pineapples, cherries, bananas, and avocados. Oral Allergy Syndrome occurs when the immune system mistakes the proteins in these raw fruits for allergenic tree pollens. This confusion triggers a localized allergic response in the mouth and throat.

Participants chewed their known allergenic fruit and spat it out to trigger an immediate localized reaction. Following allergen exposure, 77 percent of subjects experienced moderate symptoms. Another 17 percent experienced severe symptoms. In total, 94 percent of the participants demonstrated moderate to severe reactions based on a standardized oral severity score. Documented reactions included swelling of the lips, throat, tongue, and cheeks, along with nasal congestion, tingling, and pain. Approximately 25 percent of the subjects reported visible swelling of their mucosal tissues. Researchers then administered a single 12 milligram dose of Anaphylm under the tongue to measure the physiological response.

Clinical investigators measured the time required for symptom relief and the time to reach maximum plasma concentration. The trial data showed that all instances of active swelling resolved completely within five minutes of administration. The data also revealed that 50 percent of all symptoms across all subjects disappeared entirely within five minutes. The median time to complete symptom resolution across all subjects was 12 minutes. This performance compared favorably to the baseline screening process. During the initial screening without any medical intervention, the median time for symptoms to subside naturally was 74 minutes.

Pharmacokinetic measurements confirmed that oral physiological changes do not alter the absorption profile of Anaphylm. The time to maximum plasma concentration remained at 12 minutes for subjects with and without allergen exposure. This absorption rate was significantly faster than intramuscular epinephrine injections. Intramuscular injections averaged 50 minutes to reach peak concentration in similar testing conditions. The maximum plasma concentration levels were also comparable between the allergen exposure group and the non exposure group. The clinical data proved that the presence of excessive saliva, localized swelling, and inflamed tissues does not impede the drug from entering the bloodstream.

The trial included a three period crossover design for the phase. The arms included Anaphylm with allergen exposure, Anaphylm without allergen exposure, and intramuscular epinephrine without allergen exposure. The second phase served as an optional follow up where 12 participants switched between single and repeat doses. Fifteen minutes after a single dose of Anaphylm, approximately 20 percent of oral allergy symptoms remained on average. Researchers administered a second dose to these specific patients. All remaining symptoms resolved within five to 10 minutes following the second dose. There were no reports of difficulty administering the film to subjects experiencing active reactions.

Safety data from the Oral Allergy Syndrome study aligned with previous trials involving healthy subjects. The medication was well tolerated during active allergic reactions. Reported side effects were mild to moderate and resolved without medical intervention. After receiving a second dose, four out of 24 patients reported heart palpitations. Two patients reported nausea. Physicians noted cases of mild irritation or redness at the administration site. No serious adverse events occurred during the testing period.

The clinical results confirm that sublingual epinephrine delivery remains viable even when mucosal tissues are compromised by an allergic reaction. The polymer matrix based prodrug begins dissolving on contact. The medication does not require water or swallowing. This feature is highly beneficial for patients experiencing throat swelling and airway constriction. The data from the 2024 and 2025 trials provided the regulatory foundation for the pediatric studies that followed. The consistent absorption rates across different patient conditions demonstrate the reliability of the sublingual film format. Medical professionals can rely on this data to understand how the medication performs in real world scenarios outside of controlled healthy subject trials.

Aquestive fortified its intellectual property portfolio ahead of the regulatory decision. The United States Patent and Trademark Office issued two serious patents in October 2025. Patent numbers 12, 427, 121 and 12, 443, 850 cover the enhanced delivery epinephrine compositions. These patents protect the proprietary polymer matrix and prodrug formulation. The core patents are expected to expire on May 4, 2037.

The newly granted patents strengthen a broad intellectual property shield for the company. Aquestive holds at least 110 granted patents worldwide. The United States accounts for at least 28 of these granted patents. The company also maintains more than 150 pending patent applications globally. These legal protections cover the PharmFilm and Adrenaverse delivery platforms. The specific claims in the October 2025 grants protect the exact composition of matter for Anaphylm. The formulation uses a specialized polymer matrix combined with permeation enhancers and pH modifiers. These components work together to ensure the dibutepinephrine prodrug absorbs rapidly through the sublingual mucosa. The engineering process requires precise calibration of the solvent systems to maintain the stability of the active ingredients.

Developing this proprietary technology required substantial financial investment. Aquestive reported $20. 3 million in research and development expenses for the full year 2024. The company spent an additional $17. 2 million on research and development during 2025. of these funds supported the clinical trials and patent prosecution for the Anaphylm program. The financial commitment allowed formulation engineers to test various solvent systems and excipients. The resulting patented design maximizes transcellular and intercellular transport across the mucosal membrane. The research teams conducted extensive ex vivo permeation screening using excised tissue to determine the exact mix of ingredients needed to maximize solubility.

The patent expiration date of May 4, 2037, provides a long window of market exclusivity. This timeline is serious for the commercial strategy of the company. Generic competitors cannot legally produce a sublingual epinephrine film using the same polymer blends or permeation enhancers until the patents expire. The legal framework prevents rivals from copying the exact method used to convert the inactive prodrug into active epinephrine. The composition of matter patents offer the strongest form of intellectual property protection available in the pharmaceutical industry. The company secured these rights after demonstrating that the specific combination of the prodrug and the polymer film was entirely original and not obvious to other experts in the field.

The Adrenaverse platform represents a specific application of the broader PharmFilm technology. The company engineered the film to dissolve immediately upon contact with saliva. The patented process ensures the active pharmaceutical ingredient remains uniformly distributed throughout the physical film. This uniformity guarantees that each dose delivers the exact amount of epinephrine required to halt a severe allergic reaction. The United States Patent and Trademark Office recognized the originality of this specific combination of polymers and prodrugs. The patents detail the exact pharmacokinetic parameters achieved by the film. The documents specify the time to maximum concentration and the area under the curve for the absorption profile.

Aquestive executives view the intellectual property estate as a primary corporate asset. The company actively defends its patents against infringement. The legal strategy involves filing continuation applications to expand the scope of the original claims. The 150 pending applications worldwide indicate a deliberate effort to secure international market rights. The company plans to submit regulatory applications for Anaphylm in Canada and the European Union in 2026. The global patent strategy aligns with these international expansion plans. The European Medicines Agency already confirmed that no further clinical trials are needed prior to the regulatory approval submission in Europe. The international patents protect the product in these new markets.

The rejection of the New Drug Application by the Food and Drug Administration does not invalidate the underlying patents. The intellectual property remains fully intact and enforceable. The regulatory delay simply postpones the commercialization of the protected technology. The company retains the exclusive legal right to manufacture and sell the dibutepinephrine sublingual film once regulatory demands are cleared. The financial value of the patents depends entirely on the eventual approval of the drug. The company must resolve the labeling deficiencies identified in the Complete Response Letter to monetize the protected technology. The patents ensure that no other manufacturer can capture the market while Aquestive addresses the regulatory demands.

The race for needle free epinephrine is highly competitive. ARS Pharmaceuticals secured FDA approval for its neffy nasal spray in August 2024. The 2 milligram nasal spray serves adults and children weighing at least 66 pounds. A lower dose neffy for smaller children gained approval in March 2025. Aquestive must overcome its regulatory delays to capture market share from this established competitor.

ARS Pharmaceuticals launched the 2 milligram neffy dose following the August 9, 2024 approval. The company priced the two dose package at $199 for cash buyers. For insured patients, copay programs cap the out of pocket cost at $25. The Food and Drug Administration then approved the 1 milligram dose on March 5, 2025. This lower dose covers children weighing between 33 and 66 pounds. ARS Pharmaceuticals expanded its reach internationally by securing approvals in Europe and Australia by late 2025. The company reported a $4 million regulatory milestone payment from its Chinese partner Pediatrix Therapeutics in December 2025.

The manufacturer reported that 19 insurers covered neffy without prior authorization by May 2025. These insurers include United Healthcare, Express Scripts, Cigna Healthcare, OptumRx, Navitus Health Systems, and Tricare. The company secured a shelf life of 30 months for the 2 milligram dose. The product withstands temperature exposure up to 122 degrees Fahrenheit. If accidentally frozen, users can thaw and administer the spray. This temperature resilience offers a distinct advantage over traditional autoinjectors. Traditional autoinjectors degrade when exposed to extreme heat or cold.

Orexo AB entered the race with a powder based nasal epinephrine product named OX640. The Swedish pharmaceutical company announced positive results from its clinical study on January 10, 2025. The trial evaluated 30 subjects with and without allergic rhinitis. The data showed that OX640 achieved clinically relevant plasma levels of epinephrine faster than a standard intramuscular injection. The absorption rate increased when subjects experienced allergic rhinitis symptoms. Orexo uses a proprietary technology called AmorphOX to formulate the dry powder. The company plans to finalize its commercial dose based on these 2025 trial results.

Orexo AB conducted its initial Phase 1 study to prove that the powder formulation achieves epinephrine plasma levels comparable to the EpiPen. The subsequent Phase 2 study involved 30 subjects. Researchers administered a small dose of an allergen into the noses of the subjects to trigger an allergic reaction before giving the nasal medication. The trial measured blood pressure and heart rate alongside epinephrine absorption. The powder formulation produced more pronounced increases in blood pressure and heart rate than the intramuscular injection. These cardiovascular responses are essential for treating anaphylaxis. Orexo partnered with Swedish Orphan Biovitrum in February 2024 to advance the AmorphOX platform.

Bryn Pharma is developing a two spray nasal device called Utuly. The company dosed the participant in a new clinical trial on June 25, 2025. The trial evaluates an upgraded device designed to deliver two doses from a single unit. Bryn Pharma previously received Fast Track designation from the Food and Drug Administration for this product. The company expects to release the trial data by the third quarter of 2025. The Utuly device aims to achieve higher therapeutic epinephrine levels than the standard 0. 3 milligram autoinjector.

Bryn Pharma focuses on an expedited regulatory pathway for Utuly. This pathway allows the company to rely on existing data for the active ingredient. The Utuly device delivers 6. 6 milligrams of epinephrine per spray. Patients administer one spray in each nostril for a total dosage of 13. 2 milligrams. A November 2023 open label trial compared this 13. 2 milligram dose to a single 0. 3 milligram injection. The trial included adults with and without nasal congestion. The high dose compensates for the lower absorption rate of the nasal mucosa compared to muscle tissue. The upgraded device tested in the June 2025 trial features an integrated dose indicator for clear user feedback.

The traditional epinephrine autoinjector market remains dominant. Viatris manufactures the EpiPen. Sanofi produces the Auvi Q device. Teva Pharmaceuticals supplies generic autoinjectors. These established products require a needle injection into the thigh muscle. Patients frequently hesitate to use needle based devices during an allergic emergency. Research indicates that 56 percent of caregivers fear using needle based autoinjectors on children. This hesitation delays treatment and increases the risk of severe reactions. The needle free alternatives aim to solve this exact problem.

Aquestive Therapeutics must navigate this crowded field. The company developed Anaphylm as a sublingual film. The film dissolves under the tongue to deliver epinephrine. This delivery route avoids the nasal congestion variables that complicate nasal sprays. Yet the Food and Drug Administration requires extensive pharmacokinetic data to prove that the sublingual absorption matches the established injection profile. The regulatory delays give ARS Pharmaceuticals a significant head start in securing formulary placement and changing prescriber habits.

Chief Executive Officer Daniel Barber addressed the regulatory failure directly. Barber stated that the company is encouraged that the problem are limited to human factors and a supportive pharmacokinetics study. He emphasized that the FDA provided labeling comments that inform the final product label. Barber reiterated total confidence in the effectiveness and safety of the sublingual film.

Barber detailed the specific human factors data during a corporate presentation. The human factors validation study included 166 participants. Only one individual failed to open the packaging pouch. This individual was a child operating a child resistant pouch. Six participants tore the sublingual film while opening the package. Barber clarified that these six individuals still received a full dose from the torn film. The company shipped over 2. 5 billion doses of similar film products between 2010 and 2025. During this period, Aquestive recorded exactly one complaint regarding a torn pouch.

The regulatory agency did not question the core efficacy of the medication. Barber confirmed the FDA noted no deficiencies regarding pharmacokinetics bracketing, repeat dose safety, or sustainability of the product performance. The agency also requested no new pivotal clinical trials. The FDA raised no concerns regarding chemistry, manufacturing, or controls. The required remediation involves packaging modifications, updated instructions, and a single supportive pharmacokinetics study. The agency stated the human factors and pharmacokinetics studies can proceed concurrently.

Aquestive maintains a strong financial position to execute the required studies. The company reported $129. 1 million in cash and cash equivalents as of September 30, 2025. In August 2025, Aquestive secured a $75 million strategic funding agreement with RTW Investments. This capital supports the planned commercial launch and ongoing regulatory activities. Barber expects to request a Type A meeting with the FDA within 30 days of the regulatory decision. The company plans the third quarter of 2026 for the New Drug Application resubmission.

Barber addressed the specific labeling comments provided by the regulatory agency. The FDA offered guidance that shapes the final product label upon future approval. The company plans to confirm the effectiveness of these labeling revisions in the upcoming human factors validation study. Aquestive already designed a protocol for this new study and intends to move the process forward rapidly. The requested pharmacokinetics study relates directly to the FDA feedback about film placement. Barber described this additional study as simple and easy to perform.

The executive team confirmed that the commercial infrastructure remains intact. Aquestive built commercial readiness across distribution, medical affairs, and marketing channels throughout 2025. The company views the allergy market as growing and notes that patient preference heavily favors oral delivery methods. The leadership team believes the commercial preparations are fully transferable to the new timeline. Aquestive also continues to advance regulatory discussions in Canada and the European Union.

20 Essential Questions Answered

1. Did the FDA question Anaphylm efficacy? No, the FDA did not question the drug efficacy.

2. Were there safety signals raised? No new safety signals appeared in the response.

3. Did the FDA require new pivotal clinical trials? The agency did not demand new pivotal clinical trials.

4. What were the primary FDA concerns? The concerns centered on human factors and packaging.

5. How participants were in the human factors study? The study included 166 participants.

6. Did any adults fail to open the pouch? No adults failed to open the pouch.

7. How participants tore the film? Six participants tore the film during the study.

8. Did torn films deliver a full dose? Yes, torn films still delivered a full dose.

9. What did the FDA request regarding pharmacokinetics? The FDA requested a single supportive pharmacokinetics study.

10. Does the company plan to change the packaging? Aquestive plans to modify the packaging.

11. When does Aquestive meet with the FDA? The company expects a Type A meeting within 30 days.

12. When is the planned NDA resubmission? Aquestive plans the third quarter of 2026 for resubmission.

13. Did the FDA note manufacturing problems? The FDA noted no chemistry or manufacturing defects.

14. How much cash did Aquestive report in late 2025? The company reported $129. 1 million in cash as of September 30, 2025.

15. What strategic funding supports the launch? Aquestive secured a $75 million agreement with RTW Investments in August 2025.

16. Who is the CEO of Aquestive Therapeutics? Daniel Barber serves as the Chief Executive Officer.

17. How doses of similar products has Aquestive shipped? The company has shipped over 2. 5 billion doses.

18. Over what timeframe were these doses shipped? The shipments occurred between 2010 and 2025.

19. How complaints about torn pouches were recorded historically? The company recorded only one complaint about a torn pouch.

20. Are European regulatory activities continuing? Yes, the company continues regulatory activities in Europe and Canada.

Time is the most expensive variable in pharmaceutical development. Aquestive plans to request a Type A meeting with the FDA to align on the exact resubmission requirements. The company estimates it resubmit the New Drug Application in the third quarter of 2026. This timeline assumes rapid completion of the new human factors validation and pharmacokinetics studies.

The regulatory framework provides a specific process for delayed development programs. Aquestive must submit a formal meeting request and a detailed briefing package to the regulatory agency. The agency reviews the request and schedules a Type A meeting within 30 days of receipt. Company executives plan to use this meeting to confirm the exact parameters of the new human factors validation study and the requested pharmacokinetic study. The briefing package includes the proposed study designs for these new trials. The package must also contain the updated instructions for use and the modified pouch designs. The agency provides direct feedback on the trial designs during the meeting. This is necessary before the company can begin enrolling participants. The official record of this meeting dictates the exact requirements for the resubmission.

The current delay contrasts sharply with the original development schedule. Aquestive completed a pre New Drug Application meeting with regulators in December 2024. The company submitted the original application in March 2025. Regulators accepted the submission in June 2025 and assigned a target action date of January 31 2026. The agency issued the Complete Response Letter on January 30 2026. This schedule shows a standard ten month review period for the initial application. The rejection resets the regulatory clock entirely. The company must navigate a new sequence of regulatory steps. The original schedule anticipated a commercial launch in the quarter of 2026. The revised schedule pushes all commercialization activities into the following year.

The third quarter 2026 resubmission target depends on the rapid execution of two specific studies. The company must conduct a new human factors validation study. The original study included 166 participants and tested whether individuals could use the medication correctly in a simulated emergency scenario. The new trial tests modified pouch opening instructions and updated carton labeling. The company must also complete a new pharmacokinetic study. Regulators requested this study to evaluate the packaging modifications and assess film placement. Clinical teams must recruit new participants, administer the modified product, and analyze the resulting blood concentration data. Aquestive must compile the data from both studies into a complete resubmission package. The data analysis phase alone can take several weeks following the completion of dosing.

Once the company submits the new data, the regulatory agency classifies the resubmission. The agency categorizes resubmissions into two distinct classes. Class 1 resubmissions require a two month review period and involve minor labeling changes or final safety updates. Class 2 resubmissions require a six month review period. The inclusion of new clinical data from the pharmacokinetic study triggers a Class 2 designation. A six month review period pushes the new target action date into the quarter of 2027. This extended schedule delays the expected market entry by at least one full year. The agency could also require an Advisory Committee meeting during this new review period. The regulators previously noted that a Pulmonary Allergy Drugs Advisory Committee might be necessary to evaluate the medication.

Extended development schedules require significant capital reserves. Aquestive secured a 75 million dollar funding agreement with RTW Investments in August 2025. This capital injection provides the financial runway needed to complete the new studies. The company reported 93 million dollars in cash and cash equivalents at the end of 2024. The August 2025 funding agreement ensures the company can sustain operations through the extended regulatory review period. The financial reserves allow the clinical team to execute the required trials without immediate capital constraints. The company plans to allocate a portion of these funds to manufacture the modified packaging for the new clinical trials. The remaining capital supports ongoing pre commercialization activities while the regulatory review proceeds.

The data illustrates the financial damage inflicted by the regulatory rejection. The chart tracks the stock price collapse and the remaining cash reserves.

Aquestive Therapeutics entered 2026 with a heavily depleted balance sheet. The company recorded a net loss of $83. 8 million for the full year 2025. This figure nearly doubled the $44. 1 million net loss reported in 2024. The financial drain stemmed from high commercialization expenses and $14. 3 million in legal costs. Total revenue for 2025 fell 23 percent to $44. 5 million. The decline was driven by lower manufacturing and supply income from licensed products like Suboxone. The company relied heavily on its legacy manufacturing business to fund its research and development pipeline. The revenue drop placed immense pressure on the Anaphylm approval timeline. The company needed the new product to offset the declining sales of older medications.

To prepare for the anticipated Anaphylm launch, executives executed a major capital raise in August 2025. The company sold 21. 25 million shares of common stock at $4. 00 per share. This underwritten offering generated $85 million in gross proceeds. The cash infusion boosted the year end reserves to $121. 2 million. The funds were strictly allocated to support the commercial rollout of the sublingual epinephrine film. The regulatory rejection forces the company to burn through these reserves without the expected product revenue. The company spent heavily on sales force development, marketing programs, and distribution networks throughout late 2025. These investments yield zero return until the regulatory agency clears the product for market entry.

The market reaction to the Complete Response Letter was immediate and severe. Shares of Aquestive Therapeutics traded near $6. 21 prior to the January 30 decision. The stock price collapsed to $3. 91 following the announcement. The selloff erased millions in shareholder value and dropped the market capitalization to $394. 6 million. Trading volume spiked as institutional investors adjusted their positions based on the delayed approval timeline. The stock had previously reached a 52 week high of $7. 55 during the lead up to the target action date. The sudden drop reflects the binary nature of biotechnology investments. The market priced in a high probability of approval based on the clinical data. The rejection caught investors off guard and triggered a rapid repricing of the asset.

The regulatory denial also blocked access to conditional capital. In August 2025, Aquestive signed a $75 million strategic funding agreement with RTW Investments. This financing was strictly contingent upon the United States Food and Drug Administration approving Anaphylm. The Complete Response Letter prevents the company from drawing on these funds. Executives must finance ongoing operations and a planned third quarter 2026 New Drug Application resubmission using only their existing cash. The company extended the marketing approval deadline for the RTW agreement to June 30, 2027. Aquestive agreed to problem RTW a warrant for up to 375, 000 shares at $4. 00 per share to secure this extension.

The financial projections for 2026 show continued capital depletion. Management guided for 2026 revenue between $46 million and $50 million. The company expects a non GAAP adjusted EBITDA loss of $30 million to $35 million for the year. The current cash reserves provide a runway into 2027. The delayed commercialization timeline places heavy pressure on the remaining capital. The company must maintain its sales infrastructure and fund additional pharmacokinetic studies requested by the regulatory agency. The combination of debt service, research costs, and commercial readiness expenses rapidly consumes the $121. 2 million cash balance.

Aquestive carries a heavy debt load that complicates its financial recovery. The company holds 13. 5 percent notes that require quarterly principal payments. These high interest obligations drain cash that would otherwise support clinical development. The regulatory delay means the company must service this debt without the projected cash flow from Anaphylm sales. The management team must carefully balance debt repayment against the costs of running the requested pharmacokinetic study. Any miscalculation could force the company into another dilutive equity raise before the 2027 approval window opens.

The financial damage extends beyond immediate cash burn. The delay gives competitors additional time to capture market share. Alternative epinephrine delivery systems gained approval in 2024. These rival products are already establishing commercial footholds while Aquestive remains locked in the regulatory process. The company projected peak annual sales for Anaphylm to reach hundreds of millions of dollars. Every month of delay represents lost revenue and allows competitors to secure exclusive contracts with pharmacy benefit managers. The final financial cost of the Complete Response Letter far exceeds the immediate drop in stock price.

Aquestive operates as the exclusive manufacturer of its licensed products. The company use its proprietary PharmFilm technology platform. The manufacturing infrastructure remains fully operational even with the regulatory delay. The packaging modifications require retooling the primary pouch sealing process. The company confirmed that chemistry and manufacturing controls passed FDA inspection without any deficiencies.

Aquestive manages two current Good Manufacturing Practice facilities in Portage, Indiana. The company expanded these sites in 2022 to add secondary packaging and serialization capabilities. The total manufacturing footprint exceeds 90, 000 square feet. The infrastructure includes an 8, 400 square foot production facility leased through March 2028 and a separate 73, 000 square foot building. The company produced and shipped more than 2. 5 billion doses of oral film products globally by the end of 2025. The production lines handle blending batch sizes ranging from 45 to 500 liters. The facilities maintain active registrations with the Drug Enforcement Administration for Schedule II through V substances.

The Anaphylm product requires specialized packaging to protect the polymer matrix film. The primary packaging consists of a flexible foil pouch. The pouch is thinner and smaller than a standard credit card. The design protects the film from weather excursions like rain and direct sunlight. The United States Food and Drug Administration identified human factors problems during the validation study. Six participants tore the film while opening the pouch. One child participant failed to open the child resistant pouch entirely. Aquestive modified the pouch opening method and updated the printed instructions to resolve this matter. The company must execute a new human factors validation study to prove the packaging changes work.

The Portage facilities operate under strict Drug Supply Chain Security Act compliance. The 2022 expansion integrated automated pouch cartoning lines with full serialization capabilities. This technology ensures complete product traceability across the supply chain. The company completed a 24, 000 square foot expansion of its analytical laboratories to support quality control testing and raw material release. The laboratories feature built in redundancy systems for data archival and remote storage. The regulatory agency did not request any new comparability data for the manufacturing process. The repeat dose safety and sustainability data submitted in the original application remain valid.

The physical specifications of the Anaphylm product dictate the manufacturing requirements. Each dose of the polymer matrix epinephrine prodrug weighs less than one ounce and mirrors the size of a standard postage stamp. The manufacturing process formulates the film to dissolve immediately upon contact with the oral mucosa. The production lines do not need to account for liquid suspension stability. The final product requires no water or swallowing for administration. The company applies 20 years of manufacturing experience to produce these specialized films. The production team secured six prior FDA approvals for different film products using this exact manufacturing method.

Aquestive operates as a contract development and manufacturing organization alongside its proprietary pipeline. The Portage facilities produce commercial volumes of licensed oral films including Suboxone and Sympazan. The manufacturing sites maintain compliance with international regulatory bodies. The facilities passed inspections by the Therapeutic Goods Administration to support global distribution. The company uses this established supply chain to support international expansion for Anaphylm. Aquestive plans to submit a New Drug Submission to Health Canada in the half of 2026. The European Medicines Agency confirmed the company can submit a marketing authorization application in the second half of 2026 without conducting additional clinical trials.

The manufacturing supply chain relies on integrated testing capabilities. The 24, 000 square foot laboratory expansion supports immediate quality control testing. The facility executes International Council for Harmonisation stability studies on site. The laboratory technicians perform raw material release testing before any chemical enters the blending phase. The finished product release testing occurs within the same facility to prevent shipping delays. The data archival systems include remote storage capabilities to protect manufacturing records. This infrastructure ensures the company can expand production rapidly upon regulatory approval.

Aquestive reported 44. 5 million dollars in licensed product revenue for 2025. The company maintains sufficient capital to fund the Anaphylm approval process and pre launch manufacturing activities. The executive team confirmed that the human factors validation study and the required pharmacokinetic study run in parallel to accelerate the resubmission timeline. The company controls the entire production process from formulation blending to secondary packaging within the United States. The localized supply chain protects the final product from international shipping delays and cross border trade disputes.

Severe allergic reactions require immediate intervention. Epinephrine remains the only approved line treatment for anaphylaxis. Medical professionals note that patients hesitate to use auto injectors due to needle phobia. The sublingual film offers a discreet and highly portable alternative. The allergy community awaits the 2026 resubmission to see if this needle free option reach the market.

20 Essential Questions on the Future of Anaphylaxis Treatment

1. What percentage of adults experience anaphylaxis? About 5. 1 percent of adults experience anaphylaxis.

2. How adults live without an active epinephrine prescription? Data shows 52 percent of patients live without a prescription.

3. What percentage of patients do not carry their device? Studies indicate 60 percent do not have their device available.

4. How large is the global epinephrine market? The market reached 2. 05 billion dollars in 2023.

5. What is the projected market value for 2029? Analysts project a 3. 40 billion dollar market by 2029.

6. What percentage of parents fear using auto injectors? Surveys reveal 56 percent of parents fear using the device.

7. How patients use the auto injector correctly? Only 21 percent demonstrate the correct steps.

8. What is the median time to peak concentration for Anaphylm? The film reaches peak concentration in 12 minutes.

9. How does this compare to a standard syringe? A syringe takes 50 minutes to reach peak concentration.

10. How children participated in the Anaphylm pediatric trial? The trial included 32 children.

11. What age group did the pediatric trial cover? The trial covered children ages 7 to 17.

12. What was the Anaphylm dose in the pediatric trial? The children received a 12 milligram dose.

13. When does Aquestive plan to launch Anaphylm? The company plans for the quarter of 2026.

14. What percentage of anaphylaxis cases involve food allergies? Food triggers account for 32 to 37 percent of cases.

15. What percentage of anaphylaxis cases involve medications? Medications cause 21 to 58. 8 percent of reactions.

16. How deaths occur annually from anaphylaxis? The condition causes 225 deaths per year.

17. What percentage of patients seek treatment within 15 minutes? Only 42 percent seek immediate treatment.

18. How patients self administer epinephrine? Only 11 percent self administer the medication.

19. What percentage of patients go to the hospital? Hospital visits occur in 34 percent of cases.

20. What percentage of patients treat themselves with antihistamines? Antihistamines are used by 27 percent of patients.

Market and Patient Behavior

The global epinephrine auto injector market reached 2. 05 billion dollars in 2023. Financial analysts project the market to reach 3. 40 billion dollars by 2029. This growth reflects a steady increase in diagnosed food and medication allergies. Food triggers account for 32 to 37 percent of all anaphylaxis cases. Medications cause between 21 and 58. 8 percent of severe reactions. The sheer volume of patients requiring emergency medication creates a massive demand for accessible treatments.

Patient compliance remains a serious problem in allergy management. an absence of proper training among prescribed users. Only 21 percent of participants in a recent clinical evaluation could demonstrate all correct steps for using an auto injector. Also, 56 percent of parents of children with peanut allergies expressed fear regarding the use of the device. This fear results in delayed treatment during emergencies. Only 11 percent of patients self administer epinephrine during an allergic episode. Another 27 percent incorrectly treat themselves with antihistamines. Only 42 percent seek medical treatment within 15 minutes of symptom onset.

Clinical Metrics for Sublingual Epinephrine

Aquestive Therapeutics developed Anaphylm to solve these compliance failures. The sublingual film dissolves under the tongue and requires no needles. Clinical trial data from 2024 and 2025 demonstrate the pharmacokinetic viability of this method. In adult trials, Anaphylm reached peak blood concentrations of epinephrine in a median time of 12 minutes. This matches the 12 minute median time for the standard EpiPen. Other delivery methods take longer. The Neffy nasal spray takes 20 minutes to reach peak concentration. The AUVI Q auto injector takes 30 minutes. A standard manual syringe takes 50 minutes.

The company completed a pivotal pediatric study in late 2025. The trial included 32 children ages 7 to 17. Each participant weighed at least 66 pounds and had a history of severe allergic reactions. The children received a single 12 milligram dose of the sublingual film. Researchers measured blood epinephrine levels, heart rate, and blood pressure. The pediatric responses matched the adult data. The children achieved a mean baseline adjusted epinephrine concentration of 280 picograms per milliliter at 10 minutes. Adults achieved 330 picograms per milliliter in the same timeframe. The product proved safe and well tolerated across all age groups.

Comparative Delivery method

Median Time to Peak Epinephrine Concentration (Minutes) Anaphylm (12 min) EpiPen (12 min) Neffy (20 min) AUVI Q (30 min) Syringe (50 min)

The allergy community requires reliable alternatives to traditional needles. The 2026 regulatory decision dictates the immediate future of sublingual epinephrine. Aquestive Therapeutics plans a commercial launch in the quarter of 2026 pending regulatory clearance. The introduction of a film based medication provides a new option for patients who avoid carrying or using auto injectors. The data confirms that faster administration leads to better patient outcomes. The sublingual film eliminates the physical and psychological obstacles associated with needle based emergency treatments.

1. What is Anaphylm?
Anaphylm is a sublingual dibutepinephrine film designed for the treatment of Type 1 allergic reactions.

2. Who develops Anaphylm?
Aquestive Therapeutics develops the product.

3. What decision did the FDA announce in early 2026?
The FDA issued a Complete Response Letter on January 30, 2026.

4. Did the FDA reject the clinical efficacy data?
The FDA noted no deficiencies regarding pharmacokinetics or repeat dose safety.

5. What specific matters did the FDA identify?
The agency identified human factors concerns regarding pouch opening and incorrect film placement.

6. How does Aquestive plan to respond?
The company modified the pouch opening and instructions and plans to conduct a new validation study.

7. Are new clinical trials required?
The FDA requested a single pharmacokinetic study to assess packaging modifications.

8. When is the resubmission target?
Aquestive the third quarter of 2026 for resubmission.

9. What is the target patient weight for the current application?
The application covers patients weighing 30 kilograms or more.

10. Did the company test the product in pediatric patients?
A trial involving 32 children aged 7 to 17 yielded positive pharmacokinetic results in April 2025.

11. What was the original target action date?
The original Prescription Drug User Fee Act target date was January 31, 2026.

12. How did the stock market react to the initial regulatory delay?
Aquestive stock fell 37 percent on January 9, 2026.

13. Are there legal actions pending against Aquestive?
Multiple class action securities fraud lawsuits were filed in March 2026.

14. What do the lawsuits allege?
The complaints allege the company misled investors regarding the approval timeline.

15. What is the deadline for lead plaintiff motions?
Investors have until May 4, 2026, to file motions.

16. Is the company seeking approval outside the United States?
Aquestive plans to submit applications in Canada and Europe in 2026.

17. Did European regulators require more trials?
The European Medicines Agency indicated no further clinical trials are needed prior to submission.

18. How is the product administered?
The film is placed under the tongue and dissolves without water.

19. Who is the chief executive officer of Aquestive?
Daniel Barber serves as the chief executive officer.

20. Who is the chief medical officer?
Matthew Greenhawt serves as the chief medical officer.

Market Data Chart